Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: An open-label Phase II feasibility study

Hematology/ Oncology and Stem Cell Therapy

Volumn 7, Issue 1, 2014, Pages 27-31

  Naqi, Naeem ^a   Ahmad, Shaharyar ^b   Murad, Sohail ^c   Khattak, Javaid ^a  

^a Malir National University of Medical Sciences   (Pakistan)

^b KING EDWARD MEDICAL UNIVERSITY   (Pakistan)

^c Institute of Nuclear Medicine and Oncology   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; PAKISTAN; PHASE 2 CLINICAL TRIAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DEMOGRAPHY; DEOXYCYTIDINE; FEASIBILITY STUDIES; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84896704713     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hemonc.2013.11.003     Document Type: Article

References (16)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2 2005 74 108
2. WHO World Health Organization, Cancer factsheet < http://www.who.int/ mediacentre/factsheets/fs297/en/index.html > (Feb 2012).
3. R.G. Simonetti, A. Liberati, C. Angiolini, and L. Pagliaro Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials Ann Oncol 8 2 1997 117 136
4. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 4 2008 378 390
5. X. Chenivesse, D. Franco, and C. Bréchot MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis J Hepatol 18 2 1993 168 172
6. A.X. Zhu Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11 7 2006 790 800
7. T.W. Leung, Y.Z. Patt, W.Y. Lau, S.K. Ho, S.C. Yu, and A.T. Chan et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma Clin Cancer Res 5 7 1999 1676 1681
8. S.R. Nerenstone, D.C. Ihde, and M.A. Friedman Clinical trials in primary hepatocellular carcinoma: current status and future directions Cancer Treat Rev 15 1 1988 1 31
9. Abou-Alfa GK., Johnson P, Knox J, et al. Final results from a phase II (Ph II) randomized, double-blind study of sorafenib plus doxorubicin (S + D) versus placebo plus doxorubicin (P + D) in patients (pts) with advanced hepatocellular carcinoma(AHCC). Presented at the 2008 Gastrointestinal Cancers Symposium, Orlando, FL (January 25-27, 2008; abstract 128).
10. K.M. Field, and M. Michael Part II: Liver function in oncology: towards safer chemotherapy use Lancet Oncol 9 12 2008 1181 1190
11. A.P. Venook, M.J. Egorin, G.L. Rosner, D. Hollis, S. Mani, and M. Hawkins et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and leukemia group B 9565 J Clin Oncol 18 14 2000 2780 2787
12. NCCN Guidelines (2010) practice guidelines in oncology hepatobiliary cancers. See < URL:http://www.nccn.org/professionals/physicians-gls/PDF/ hepatobiliary > [Please include date of access].
13. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 1 2009 25 34
14. S.L. Chan, F.K. Mo, P.J. Johnson, E.P. Hui, B.B. Ma, and W.M. Ho et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy J Clin Oncol 27 3 2009 446 452
15. Z. Guan, Y. Wang, S. Maoleekoonpairoj, Z. Chen, W.S. Kim, and V. Ratanatharathorn et al. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma Br J Cancer 89 10 2003 1865 1869
16. H. Ulrich-Pur, G.V. Kornek, W. Fiebiger, B. Schüll, M. Raderer, and W. Scheithauer Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine Oncology 60 4 2001 313 315